Home The Word Brain My Amedeo FAQ Privacy About   


2049 Chinese

The 20K Word Road to Mandarin Proficiency

By B. S. Kamps et al.


  Diabetes

  Free Subscription


Articles published in N Engl J Med

Retrieve available abstracts of 116 articles:
HTML format



Single Articles


    March 2024
  1. HUGHES MS, Addala A, Buckingham B
    Digital Technology for Diabetes. Reply.
    N Engl J Med. 2024;390:963-964.
    PubMed    


  2. BERG TJ
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:963.
    PubMed    


  3. TUMMINIA A, Gullo D, Frasca F
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:962-963.
    PubMed    


  4. KINNY-KOSTER B, Michalski CW, Loos M
    Digital Technology for Diabetes.
    N Engl J Med. 2024;390:962.
    PubMed    


    February 2024
  5. LINCOFF AM, Ryan DH, Esbjerg S
    Semaglutide and Cardiovascular Outcomes. Reply.
    N Engl J Med. 2024;390:768-769.
    PubMed    


  6. NEVES JS, Leite AR, Ferreira JP
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767-768.
    PubMed    


  7. CAMPBELL LA, Jenkins AV, Jackson CD
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    


  8. BELKHOURIBCHIA J
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:767.
    PubMed    


  9. BELALCAZAR LM, Kuo YF
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766-767.
    PubMed    


  10. TAQUETI VR, Shaw LJ
    Semaglutide and Cardiovascular Outcomes.
    N Engl J Med. 2024;390:766.
    PubMed    


  11. SCHWARTZ AL
    SGLT2 Inhibitors and False Positive Toxicology Tests.
    N Engl J Med. 2024;390:573-574.
    PubMed    


    January 2024
  12. DANDONA P, Chaudhuri A, Ghanim H
    More on Semaglutide in Early Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:292.
    PubMed    


  13. GAGLIA JL, Laffel LM, Patti ME
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:291.
    PubMed    


  14. WEINRAUCH LA, D'Elia JA
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:291.
    PubMed    


  15. DEVRIES JH
    More on Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2024;390:290.
    PubMed    


  16. LEE TTM, Bergford S, Murphy HR
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes. Reply.
    N Engl J Med. 2024;390:184.
    PubMed    


  17. GRZYCH G, Kim I
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2024;390:183-184.
    PubMed    


  18. VIVANTI AJ, Benachi A, Voican A
    Automated Insulin Delivery during Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2024;390:183.
    PubMed    


  19. LIU MJ, Li J
    Necrobiosis Lipoidica.
    N Engl J Med. 2024;390:70.
    PubMed    


    December 2023
  20. WHARTON S, Konig M
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity. Reply.
    N Engl J Med. 2023;389:2304-2305.
    PubMed    


  21. POURKARIM F, Entezari-Maleki T
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303-2304.
    PubMed    


  22. PRESTON W
    GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023;389:2303.
    PubMed    


  23. LUDVIGSSON J
    Immune Interventions at Onset of Type 1 Diabetes - Finally, a Bit of Hope.
    N Engl J Med. 2023;389:2199-2201.
    PubMed    


  24. WAIBEL M, Wentworth JM, So M, Couper JJ, et al
    Baricitinib and beta-Cell Function in Patients with New-Onset Type 1 Diabetes.
    N Engl J Med. 2023;389:2140-2150.
    PubMed     Abstract available


    November 2023
  25. HUGHES MS, Addala A, Buckingham B
    Digital Technology for Diabetes.
    N Engl J Med. 2023;389:2076-2086.
    PubMed    


  26. VIVANTE A, Tan W, Harrington SG, Udler MS, et al
    Case 36-2023: A 19-Year-Old Man with Diabetes and Kidney Cysts.
    N Engl J Med. 2023;389:1993-2003.
    PubMed    


  27. NEWELL-PRICE J
    Testing for Arginine Vasopressin Deficiency.
    N Engl J Med. 2023;389:1920-1921.
    PubMed    


  28. LINCOFF AM, Brown-Frandsen K, Colhoun HM, Deanfield J, et al
    Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
    N Engl J Med. 2023 Nov 11. doi: 10.1056/NEJMoa2307563.
    PubMed     Abstract available


    October 2023
  29. ROSENSTOCK J, Gowda A, Liang B
    Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin. Reply.
    N Engl J Med. 2023;389:1533.
    PubMed    


  30. MISBIN RI
    Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    N Engl J Med. 2023;389:1532-1533.
    PubMed    


  31. SUGIYAMA K
    Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    N Engl J Med. 2023;389:1532.
    PubMed    


  32. ABEL ED, Ingelfinger JR, Linhales Barker S, Peek M, et al
    Type 2 Diabetes - Controlling the Epidemic, Episode 4: Understanding Old and New Therapies for Diabetes.
    N Engl J Med. 2023;389:e31.
    PubMed    


  33. RAMOS EL, Dayan CM, Chatenoud L, Sumnik Z, et al
    Teplizumab and beta-Cell Function in Newly Diagnosed Type 1 Diabetes.
    N Engl J Med. 2023 Oct 18. doi: 10.1056/NEJMoa2308743.
    PubMed     Abstract available


  34. LEE TTM, Collett C, Bergford S, Hartnell S, et al
    Automated Insulin Delivery in Women with Pregnancy Complicated by Type 1 Diabetes.
    N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMoa2303911.
    PubMed     Abstract available


  35. GARG SK, Polsky S
    Technology Use and Glycemic Outcomes during Pregnancy with Type 1 Diabetes.
    N Engl J Med. 2023 Oct 5. doi: 10.1056/NEJMe2310798.
    PubMed    


  36. ABEL ED, Ingelfinger JR, Linhales Barker S, Lopez D, et al
    Type 2 Diabetes - Controlling the Epidemic, Episode 3: Fostering Patient Engagement and Lifestyle Modifications.
    N Engl J Med. 2023;389:e27.
    PubMed    


    September 2023
  37. ABEL ED, Ingelfinger JR, Kolko J, Linhales Barker S, et al
    Type 2 Diabetes - Controlling the Epidemic, Episode 2: After the Diagnosis - Making a Plan and Addressing Social Determinants of Health.
    N Engl J Med. 2023;389:e23.
    PubMed    


  38. DANDONA P, Chaudhuri A, Ghanim H
    Semaglutide in Early Type 1 Diabetes.
    N Engl J Med. 2023;389:958-959.
    PubMed    


  39. ABEL ED, Giffin J, Ingelfinger JR, Peek M, et al
    Type 2 Diabetes - Controlling the Epidemic, Episode 1: Understanding and Preventing Type 2 Diabetes.
    N Engl J Med. 2023;389:e18.
    PubMed    


    August 2023
  40. ALI ZA, Landmesser U, Maehara A, Matsumura M, et al
    Optical Coherence Tomography-Guided versus Angiography-Guided PCI.
    N Engl J Med. 2023 Aug 27. doi: 10.1056/NEJMoa2305861.
    PubMed     Abstract available


  41. MAGNUSSEN C, Ojeda FM, Leong DP, Alegre-Diaz J, et al
    Global Effect of Modifiable Risk Factors on Cardiovascular Disease and Mortality.
    N Engl J Med. 2023 Aug 26. doi: 10.1056/NEJMoa2206916.
    PubMed     Abstract available


  42. KRISCHER JP, Lernmark A, Hagopian WA, Rewers MJ, et al
    SARS-CoV-2 - No Increased Islet Autoimmunity or Type 1 Diabetes in Teens.
    N Engl J Med. 2023;389:474-475.
    PubMed    


    June 2023
  43. JASTREBOFF AM, Kaplan LM, Frias JP, Wu Q, et al
    Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.
    N Engl J Med. 2023 Jun 26. doi: 10.1056/NEJMoa2301972.
    PubMed     Abstract available


  44. ROSENSTOCK J, Bain SC, Gowda A, Jodar E, et al
    Weekly Icodec versus Daily Glargine U100 in Type 2 Diabetes without Previous Insulin.
    N Engl J Med. 2023 Jun 24. doi: 10.1056/NEJMoa2303208.
    PubMed     Abstract available


  45. WHARTON S, Blevins T, Connery L, Rosenstock J, et al
    Daily Oral GLP-1 Receptor Agonist Orforglipron for Adults with Obesity.
    N Engl J Med. 2023 Jun 23. doi: 10.1056/NEJMoa2302392.
    PubMed     Abstract available


  46. LINCOFF AM, Bhasin S, Flevaris P, Mitchell LM, et al
    Cardiovascular Safety of Testosterone-Replacement Therapy.
    N Engl J Med. 2023 Jun 16. doi: 10.1056/NEJMoa2215025.
    PubMed     Abstract available


  47. WADWA RP, Beck RW, Breton MD
    Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes. Reply.
    N Engl J Med. 2023;388:2206-2207.
    PubMed    


  48. SHIBUE K
    Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.
    N Engl J Med. 2023;388:2206.
    PubMed    


  49. HSU NC, Hsu CH
    Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.
    N Engl J Med. 2023;388:2205-2206.
    PubMed    


  50. SANTORO A, Kahn BB
    Adipocyte Regulation of Insulin Sensitivity and the Risk of Type 2 Diabetes.
    N Engl J Med. 2023;388:2071-2085.
    PubMed    


    May 2023
  51. GREENE MF
    Early versus Second-Trimester Screening and Treatment for Diabetes in Pregnancy.
    N Engl J Med. 2023 May 5. doi: 10.1056/NEJMe2304543.
    PubMed    


  52. SIMMONS D, Immanuel J, Hague WM, Teede H, et al
    Treatment of Gestational Diabetes Mellitus Diagnosed Early in Pregnancy.
    N Engl J Med. 2023 May 5. doi: 10.1056/NEJMoa2214956.
    PubMed     Abstract available


    March 2023
  53. WEGHUBER D, Kelly AS, Arslanian S
    Once-Weekly Semaglutide in Adolescents with Obesity. Reply.
    N Engl J Med. 2023;388:1146.
    PubMed    


  54. MALOZOWSKI S
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145-1146.
    PubMed    


  55. SNAITH JR, Greenfield JR
    Once-Weekly Semaglutide in Adolescents with Obesity.
    N Engl J Med. 2023;388:1145.
    PubMed    


  56. BRUTTOMESSO D
    Technology in the Changing Management of Diabetes in Children.
    N Engl J Med. 2023;388:1052-1054.
    PubMed    


  57. WADWA RP, Reed ZW, Buckingham BA, DeBoer MD, et al
    Trial of Hybrid Closed-Loop Control in Young Children with Type 1 Diabetes.
    N Engl J Med. 2023;388:991-1001.
    PubMed     Abstract available


    January 2023
  58. RUSSELL SJ, Damiano ER, Calhoun P
    Randomized Trial of a Bionic Pancreas in Type 1 Diabetes. Reply.
    N Engl J Med. 2023;388:380-382.
    PubMed    


  59. KHOO TK
    Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
    N Engl J Med. 2023;388:380.
    PubMed    


  60. MURATA Y, Takita M, Kami M
    Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
    N Engl J Med. 2023;388:380.
    PubMed    


    November 2022
  61. BURNSIDE MJ, Williman JA, de Bock MI
    Open-Source Automated Insulin Delivery in Type 1 Diabetes. Reply.
    N Engl J Med. 2022;387:2007-2008.
    PubMed    


  62. SCARAMUZZA AE, Cherubini V, Rabbone I
    Open-Source Automated Insulin Delivery in Type 1 Diabetes.
    N Engl J Med. 2022;387:2006-2007.
    PubMed    


  63. MURATA Y, Takita M, Kami M
    Open-Source Automated Insulin Delivery in Type 1 Diabetes.
    N Engl J Med. 2022;387:2006.
    PubMed    


  64. DAS PRADHAN A, Glynn RJ, Fruchart JC, MacFadyen JG, et al
    Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk.
    N Engl J Med. 2022 Nov 5. doi: 10.1056/NEJMoa2210645.
    PubMed     Abstract available


  65. HERRINGTON WG, Staplin N, Wanner C, Green JB, et al
    Empagliflozin in Patients with Chronic Kidney Disease.
    N Engl J Med. 2022 Nov 4. doi: 10.1056/NEJMoa2204233.
    PubMed     Abstract available


  66. CROWTHER CA, Tran T
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes. Reply.
    N Engl J Med. 2022;387:1720-1721.
    PubMed    


  67. MOHAN V, Unnikrishnan R, Anjana RM
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
    N Engl J Med. 2022;387:1720.
    PubMed    


  68. RHOADS GG
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
    N Engl J Med. 2022;387:1719-1720.
    PubMed    


  69. SMITH GCS, Sovio U
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
    N Engl J Med. 2022;387:1719.
    PubMed    


  70. PAINTER RC, van Rijn BB, Bossuyt PMM
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
    N Engl J Med. 2022;387:1718-1719.
    PubMed    


    October 2022
  71. ARSLANIAN SA, Cox D
    Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes. Reply.
    N Engl J Med. 2022;387:1530-1531.
    PubMed    


  72. SENOO Y, Kami M
    Once-Weekly Dulaglutide for Treatment of Youths with Type 2 Diabetes.
    N Engl J Med. 2022;387:1529-1530.
    PubMed    


  73. TUTTLE KR, Jones CR, Daratha KB, Koyama AK, et al
    Incidence of Chronic Kidney Disease among Adults with Diabetes, 2015-2020.
    N Engl J Med. 2022;387:1430-1431.
    PubMed    


  74. LEELARATHNA L, Evans ML, Neupane S, Rayman G, et al
    Intermittently Scanned Continuous Glucose Monitoring for Type 1 Diabetes.
    N Engl J Med. 2022 Oct 5. doi: 10.1056/NEJMoa2205650.
    PubMed     Abstract available


    September 2022
  75. SHERR J
    Seeking Simpler Solutions with Diabetes Technology.
    N Engl J Med. 2022;387:1228-1229.
    PubMed    


  76. RUSSELL SJ, Beck RW, Damiano ER, El-Khatib FH, et al
    Multicenter, Randomized Trial of a Bionic Pancreas in Type 1 Diabetes.
    N Engl J Med. 2022;387:1161-1172.
    PubMed     Abstract available


  77. RYDEN L, Standl E
    After Metformin - Next Steps for Type 2 Diabetes with Low Cardiovascular Risk.
    N Engl J Med. 2022;387:1136-1138.
    PubMed    


  78. NATHAN DM, Lachin JM, Bebu I, Burch HB, et al
    Glycemia Reduction in Type 2 Diabetes - Microvascular and Cardiovascular Outcomes.
    N Engl J Med. 2022;387:1075-1088.
    PubMed     Abstract available


  79. NATHAN DM, Lachin JM, Balasubramanyam A, Burch HB, et al
    Glycemia Reduction in Type 2 Diabetes - Glycemic Outcomes.
    N Engl J Med. 2022;387:1063-1074.
    PubMed     Abstract available


  80. BROWN SA
    On the Path toward Expanding Treatment Options for Diabetes.
    N Engl J Med. 2022;387:935-936.
    PubMed    


  81. BOUGHTON CK, Allen JM, Ware J, Wilinska ME, et al
    Closed-Loop Therapy and Preservation of C-Peptide Secretion in Type 1 Diabetes.
    N Engl J Med. 2022;387:882-893.
    PubMed     Abstract available


  82. BURNSIDE MJ, Lewis DM, Crocket HR, Meier RA, et al
    Open-Source Automated Insulin Delivery in Type 1 Diabetes.
    N Engl J Med. 2022;387:869-881.
    PubMed     Abstract available


  83. BOLINDER J
    CLOuDs Disperse - Top-Notch Glucose Control and Residual C-Peptide Secretion.
    N Engl J Med. 2022;387:937-938.
    PubMed    


    August 2022
  84. SOLOMON SD, McMurray JJV, Claggett B, de Boer RA, et al
    Dapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    N Engl J Med. 2022 Aug 27. doi: 10.1056/NEJMoa2206286.
    PubMed     Abstract available


  85. CROWTHER CA, Samuel D, McCowan LME, Edlin R, et al
    Lower versus Higher Glycemic Criteria for Diagnosis of Gestational Diabetes.
    N Engl J Med. 2022;387:587-598.
    PubMed     Abstract available


  86. LESLIE BR, Gerwin LE
    Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;387:478.
    PubMed    


  87. HEYMAN SN, Abassi Z
    Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;387:477-478.
    PubMed    


    July 2022
  88. MUSCH DC, Chew EY
    Evidence for Step Therapy in Diabetic Macular Edema.
    N Engl J Med. 2022 Jul 14. doi: 10.1056/NEJMe2208454.
    PubMed    


  89. JHAVERI CD, Glassman AR, Ferris FL 3rd, Liu D, et al
    Aflibercept Monotherapy or Bevacizumab First for Diabetic Macular Edema.
    N Engl J Med. 2022 Jul 14. doi: 10.1056/NEJMoa2204225.
    PubMed     Abstract available


    June 2022
  90. ARSLANIAN SA, Hannon T, Zeitler P, Chao LC, et al
    Once-Weekly Dulaglutide for the Treatment of Youths with Type 2 Diabetes.
    N Engl J Med. 2022 Jun 4. doi: 10.1056/NEJMoa2204601.
    PubMed     Abstract available


  91. JASTREBOFF AM, Aronne LJ, Ahmad NN, Wharton S, et al
    Tirzepatide Once Weekly for the Treatment of Obesity.
    N Engl J Med. 2022 Jun 4. doi: 10.1056/NEJMoa2206038.
    PubMed     Abstract available


    May 2022
  92. BRAUNWALD E
    Gliflozins in the Management of Cardiovascular Disease.
    N Engl J Med. 2022;386:2024-2034.
    PubMed    


    April 2022
  93. PITT B, Joseph A, Schloemer P
    Cardiovascular Events with Finerenone in CKD and Diabetes. Reply.
    N Engl J Med. 2022;386:e43.
    PubMed    


  94. ORTIZ A, Sarafidis P, Ferro CJ
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    PubMed    


  95. GERARD AO, Laurain A, Esnault VLM
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    PubMed    


  96. KAO PH, Hsu LC
    Cardiovascular Events with Finerenone in CKD and Diabetes.
    N Engl J Med. 2022;386:e43.
    PubMed    


  97. WARE J, Hovorka R
    Closed-Loop Control in Very Young Children with Type 1 Diabetes. Reply.
    N Engl J Med. 2022;386:1482-1483.
    PubMed    


  98. RING BL
    Closed-Loop Control in Very Young Children with Type 1 Diabetes.
    N Engl J Med. 2022;386:1482.
    PubMed    


  99. MURATA Y, Takita M, Kami M
    Closed-Loop Control in Very Young Children with Type 1 Diabetes.
    N Engl J Med. 2022;386:1482.
    PubMed    


    March 2022
  100. SPERLING MA, Laffel LM
    Current Management of Glycemia in Children with Type 1 Diabetes Mellitus.
    N Engl J Med. 2022;386:1155-1164.
    PubMed    


    February 2022
  101. WING JR, Kimball A, Rengarajan M
    Case 6-2022: A 68-Year-Old Man with Fatigue, Weight Loss, and Hyperglycemia.
    N Engl J Med. 2022;386:781-787.
    PubMed    


  102. FRIAS JP, Fernandez Lando L, Brown K
    Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes. Reply.
    N Engl J Med. 2022;386:e17.
    PubMed    


  103. SANTULLI G
    Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.
    N Engl J Med. 2022;386:e17.
    PubMed    


  104. PATOULIAS D, Papadopoulos C, Doumas M
    Tirzepatide versus Semaglutide Once Weekly in Type 2 Diabetes.
    N Engl J Med. 2022;386:e17.
    PubMed    


    January 2022
  105. WARE J, Allen JM, Boughton CK, Wilinska ME, et al
    Randomized Trial of Closed-Loop Control in Very Young Children with Type 1 Diabetes.
    N Engl J Med. 2022;386:209-219.
    PubMed     Abstract available


  106. DRAIN PK
    Rapid Diagnostic Testing for SARS-CoV-2.
    N Engl J Med. 2022 Jan 7. doi: 10.1056/NEJMcp2117115.
    PubMed    


    November 2021
  107. GERSTEIN HC, Khurmi NS
    Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes. Reply.
    N Engl J Med. 2021;385:2107.
    PubMed    


  108. HE L, Zhang H
    Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes.
    N Engl J Med. 2021;385:2106-2107.
    PubMed    


  109. GROOTHOF D, Vogelpohl FA, Bakker SJL
    Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes.
    N Engl J Med. 2021;385:2106.
    PubMed    


  110. BORDERIE G, Schnebelen M, Baynat L
    Efpeglenatide and Heart and Kidney Outcomes in Type 2 Diabetes.
    N Engl J Med. 2021;385:2105-2106.
    PubMed    


  111. O'CONNELL J, Nathan DM, O'Brien T, O'Keeffe DT, et al
    Treatment of Diabetes - To Pump or Not to Pump.
    N Engl J Med. 2021;385:2092-2095.
    PubMed    


  112. BJORNSTAD P, Drews K, Zeitler PS
    Long-Term Complications in Youth-Onset Type 2 Diabetes. Reply.
    N Engl J Med. 2021;385:2016.
    PubMed    


  113. NELSON RG, Hanson RL, Knowler WC
    Long-Term Complications in Youth-Onset Type 2 Diabetes.
    N Engl J Med. 2021;385:2015.
    PubMed    


  114. YANG W, Wang C
    Long-Term Complications in Youth-Onset Type 2 Diabetes.
    N Engl J Med. 2021;385:2014-2015.
    PubMed    


    October 2021
  115. FRANCQUE SM, Bedossa P, Ratziu V, Anstee QM, et al
    A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH.
    N Engl J Med. 2021;385:1547-1558.
    PubMed     Abstract available


    August 2021
  116. PACKER M, Butler J, Zannad F, Pocock SJ, et al
    Empagliflozin and Major Renal Outcomes in Heart Failure.
    N Engl J Med. 2021 Aug 27. doi: 10.1056/NEJMc2112411.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Diabetes is free of charge.